Tumor Necrosis Factorα Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure

Patrick J. Shaw, Patricia E. Ganey, and Robert A. Roth

Department of Pharmacology and Toxicology, National Food Safety and Toxicology Center, Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan

Received July 21, 2008; accepted September 25, 2008

ABSTRACT

The use of trovafloxacin (TVX), a fluoroquinolone antibiotic, was severely restricted because of an association of TVX therapy with idiosyncratic hepatotoxicity in patients. The mechanisms underlying idiosyncratic toxicity are unknown; however, one hypothesis is that an inflammatory stress can render an individual sensitive to the drug. Previously, we reported that treatment of mice with TVX and lipopolysaccharide (LPS) induced tumor necrosis factor (TNF) α-dependent liver injury, whereas TVX or LPS treatment alone was nontoxic. The goal of this study was to elucidate the role of TNFα in TVX/LPS-induced liver injury. TNF receptor (TNFR) 1 p55−/− and TNFR2 (p75−/−) mice were protected from hepatotoxicity caused by TVX/LPS coexposure, suggesting that TVX/LPS-induced liver injury requires both TNF receptors. TNFα inhibition using etanercept significantly reduced the TVX/LPS-induced increases in the plasma concentrations of several cytokines around the time of onset of liver injury. However, despite the reduction in chemokines, etanercept treatment did not affect the TVX/LPS-induced hepatic accumulation of neutrophils. In addition, etanercept treatment attenuated TVX/LPS induction of plasminogen activator inhibitor-1, and this was associated with a reduction in hepatic fibrin deposition. Mice treated with TVX and a nontoxic dose of TNFα also developed liver injury. In summary, TNFα acts through p55 and p75 receptors to precipitate an innocuous inflammatory cascade. TVX enhances this cascade, converting it into one that results in hepatocellular injury.

The leading cause of acute liver failure in the United States is drug-induced liver injury, which represents a problem for both public health and the pharmaceutical industry (Ostapowicz et al., 2002). Drug-induced liver injury is the most common reason for restrictive regulatory actions by the United States Food and Drug Administration or pharmaceutical companies. Idiosyncratic adverse drug reactions (IADRs) are an important subset of untoward reactions and are an increasing reason for postmarket regulatory actions. Trovafloxacin (TVX), a fluoroquinolone antibiotic, is one example of a drug for which use was restricted severely because of IADRs. TVX was approved for use in the United States in 1997, and by 1999, its use was associated with 152 cases of serious hepatic events. Of these, 14 resulted in acute liver failure, five patients required liver transplants, and four died (Bertino and Fish, 2000). The mechanism by which TVX causes hepatotoxicity that is not seen with other quinolones is unknown.

One hypothesis regarding the cause of IADRs is that inflammatory stress alters the toxicity threshold of an individual, rendering a normally therapeutic dose of a drug toxic (Ganey et al., 2004). In this regard, it is interesting that human clinical studies of TVX hepatotoxicity revealed the presence of inflammatory cells in liver biopsies (Chen et al., 2000). In rats and mice, nontoxic doses of TVX and bacterial lipopolysaccharide (LPS) synergized to cause acute liver injury (Waring et al., 2006; Shaw et al., 2007). In this animal model, TVX pretreatment enhanced the LPS-induced peak in plasma tumor necrosis factor (TNF) α concentration. In addition, TNFα neutralization completely protected mice from TVX/LPS-induced liver injury (Shaw et al., 2007).

TNFα is a pleiotropic cytokine that stimulates a number of cellular responses, including proliferation, production of inflammatory mediators, up-regulation of adhesion molecules, and inflammatory mediator production.
TNFα is produced in response to several microbial products, including LPS. TNFα is a key mediator of inflammatory responses, which can result in both tissue damage and host defense. The main cellular source of TNFα is macrophages, but several other cell types produce TNFα, including mast cells, hepatic stellate cells, endothelial cells, fibroblasts, and neuronal cells (Wajant et al., 2003). TNFα plays a critical role in several models of liver injury caused by viral hepatitis, ischemia/reperfusion, or hepatotoxic doses of LPS (Colletti et al., 1999; Shimizu et al., 2005; Raftery et al., 2007).

The biological effects of TNFα are elicited via two high-affinity cell surface receptors, TNF receptor 1 (p55) and TNF receptor 2 (p75) (Locksley et al., 2001). The two TNF receptors are structurally similar but functionally different. The p55 receptor provides the key mode of TNFα signaling in most cell types. The cells of the lymphoid system are the exception, in which signaling through the p75 receptor plays a major role. The intracellular domains of p55 and p75 are the main difference between the two receptors. The intracellular portion of the p55 receptor contains a death domain, which couples the activation of receptor to caspase activation and cell death (Tartaglia et al., 1993a). The p75 receptor lacks the death domain. The activation of either receptor leads to intracellular signaling cascades, including mitogen-activated protein kinase activation and nuclear factor (NF)-κB activation. Ligand activation of the receptors is another functional difference. Membrane-bound TNFα has the ability to activate both p55 and p75 receptors (Wajant et al., 2003), whereas soluble TNFα activates only the p55 receptor and is the dominant signal for p55 activation (Grell et al., 1998).

The role of each receptor has been evaluated in several models of liver injury. The p55 receptor has been studied more extensively and is important in hepatotoxicity caused by LPS, acetaminophen, or carbon tetrachloride (Peschon et al., 1998; Morio et al., 2001; Ishida et al., 2004). In contrast, critical roles for both receptors have been shown only in a few models of hepatotoxicity, such as that induced by concanavalin A, Pseudomonas aeruginosa exotoxin A, or adenovirus (Küsters et al., 1997; Hayder et al., 1999; Schumann et al., 2000).

Materials and Methods

Materials. Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, MO). The LPS (lot 075K4038) used for all studies was derived from Escherichia coli serotype O55:B5 and had an activity of $3.3 \times 10^6$ endotoxin units/mg as determined using a colorimetric, kinetic Limulus amebocyte lysate assay purchased from Cambrex (kit no. 50-650U; East Rutherford, NJ). Recombinant murine TNFα was purchased from R&D Systems (Minneapolis, MN). Trovafloxacin was synthesized by Cayman Chemical (Ann Arbor, MI).

Animals. All animals received humane care, and all studies complied with Michigan State University guidelines. Male, 9 to 11-week-old, C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were used for all experiments. p55−/−, p75−/−, and C57Bl/6J wild-type controls were purchased from The Jackson Laboratory. They were allowed to acclimate for 1 week in a 12-h light/dark cycle. Animals were given continual access to bottled spring water and fed a standard chow (Rodent Chow/Tek8640; Harlan Teklad, Madison, WI).

Study Design and Sample Collection. Dosing protocols were the same as a previous study in which coexpression of mice to TVX and LPS caused hepatotoxicity (Shaw et al., 2007). Mice were fasted for 12 h before treatment. TVX (150 mg/kg) or its saline vehicle was administered to mice by oral gavage. The dose of TVX was chosen because it was nonhepatotoxic and synergized with LPS to cause robust liver injury without significant mortality at 15 h (Shaw et al., 2007). LPS (2 × $10^6$ EU/kg), TNFα (50 μg/kg), or saline vehicle was given intraperitoneally 3 h later. The time of LPS or TNFα administration is designated as time 0 throughout. Food was returned immediately after LPS or TNFα administration. In the etanercept studies, etanercept (8 mg/kg i.p.) was given 1 h before LPS administration. Mice were anesthetized with sodium pentobarbital (50 mg/kg i.p.) at designated times and killed by exsanguination. The left lateral liver lobe was fixed in 10% neutral buffered formalin and blocked in paraffin.

ALT Activity and Histopathology Assessment. Plasma ALT activity was measured spectrophotometrically using Infinity ALT reagent purchased from Thermo Fisher Scientific (Waltham, MA). Paraffin-embedded liver sections were cut 5 μm thick and stained with hematoxylin and eosin. Eight high-power fields were scored for necrosis. The scoring scale was set from 0 to 5, with the following criteria: 0, no necrosis; 1, mild; 2, mild to moderate; 3, moderate; 4, moderate to severe; and 5, severe. For each liver, the eight scores were averaged, and this average was considered a replicate.

Plasma Cytokine Measurements. The plasma concentrations of interferon (IFN) γ, interleukin (IL)-6, IL-10, and IL-18; monocyte chemoattractant protein (MCP)-1; vascular endothelial growth factor (VEGF); macrophage inflammatory protein (MIP)-2; keratinocyte chemoattractant (KC); and MIP-1α were measured using bead-plex kits purchased from Bio-Rad (Hercules, CA) and measured using a Bio-Plex 200 system (Bio-Rad).

Hepatic Neutrophil Accumulation. Neutrophil (PMN) immunohistochemistry was performed on 5 μm thick, paraffin-embedded liver sections as described previously (Yee et al., 2003). PMNs were stained using a rabbit anti-PMN Ig isolated from the serum of rabbits immunized with rat PMNs (Hewett et al., 1992). Hepatic PMN accumulation was quantified by counting the number of PMNs in six to 10 randomly selected, high-power fields (400×) for each liver.

Hemostatic System Measurements. Plasma thrombin/antithrombin III (TAT) dimers were measured using the Enzymotat enzyme-linked immunosorbent assay kit purchased from Dade Behring, Inc. (Deerfield, IL). Active PA-1 plasma concentration was measured using an enzyme-linked immunosorbent assay kit purchased from Molecular Innovations (Southfield, MI). Hepatic fibrin immunohistochemistry and estimation of deposition were done following the protocol described previously with a slight modification (Coppel et al., 2002), i.e., artificial fibrin staining seen within vessel lumens in all treatment groups was removed from quantification calculations. Vehicle controls were used to establish the threshold fluorescence. Morphometric data are expressed as the fraction of pixels for which the fluorescence exceeded the threshold.

Statistical Analyses. All bar graph results are presented as mean ± S.E.M. A one- or two-way analysis of variance was used as appropriate after data normalization. All multiple pairwise comparisons were done using Tukey’s test. The criterion for significance was $p < 0.05$. Histopathological scores were compared using analysis of variance on ranks.

Results

p55−/− and p75−/− Mice Are Protected from TVX/LPS-Induced Liver Injury. To determine the contribution of each TNF receptor to TVX/LPS-induced liver injury,
p55+/− or p75+/− mice were treated with TVX/LPS as described under Materials and Methods. TVX/LPS coexposure caused significant liver injury at 15 h in control (wild-type) mice. Both p55+/− mice and p75+/− mice were resistant to TVX/LPS-induced liver injury (Fig. 1). p75+/− mice were completely protected from TVX/LPS-induced liver injury and had significantly reduced plasma ALT activity compared with control and p55+/− mice (Fig. 1). Histopathologic examination of livers corroborated this result, inasmuch as lesions of hepatocellular necrosis were decreased in p55+/− mice and p75+/− mice compared with wild-type mice (Fig. 1; Table 1). All of the wild-type mice treated with TVX/LPS developed at least moderate hepatocellular necrosis. In contrast, none of the lesions in the p55+/− or p75+/− mice treated with TVX/LPS progressed beyond mild necrosis (Table 1).

**TNFα Neutralization Attenuates TVX/LPS Induction of Inflammatory Cytokines and Chemokines.** In a previous study, treatment with etanercept, which is a mimic of the soluble p75 receptor, reduced TVX/LPS-induced increase in plasma TNFα concentration and protected mice from TVX/LPS-induced liver injury (Shaw et al., 2007). TVX/LPS-treated mice were dosed with etanercept to determine the effects of TNFα on the induction of proinflammatory cytokines and chemokines at 4.5 h, a time near the onset of liver injury (Shaw et al., 2008). TNFα inhibition attenuated the TVX/LPS-mediated induction of IFNγ, IL-6, IL-10, MCP-1, and VEGF (Fig. 2). The increase in IL-1β plasma concentration after TVX/LPS treatment was not changed by etanercept treatment (Fig. 2). TNFα neutralization significantly reduced the TVX/LPS induction of chemokines MIP-2, KC, and MIP-1α (Fig. 3).

**TNFα Neutralization Attenuates TVX/LPS-Induced Hemostatic System Activation.** The coagulation system plays an important role in TVX/LPS-induced pathogenesis (Fullerton et al., 2008). To determine whether TNFα plays a role in TVX/LPS-induced coagulation system activation, TVX/LPS-treated mice were treated with etanercept and killed at 4.5 h. The dose of etanercept markedly reduced the TVX/LPS-induced release of TNFα in this model (Shaw et al., 2007). Plasma TAT dimers, measured as a biomarker of coagulation system activation, were significantly increased in TVX/LPS-treated mice (Fig. 5A). Etanercept treatment caused a trend toward reduction in plasma TAT dimers, but this difference was not statistically significant. The plasma concentration of active PAI-1, an inhibitor of the fibrinolytic system, was increased by TVX/LPS coexposure (Fig. 5B). Fibrin deposition in tissue occurs if the rate of coagulation system activation exceeds the rate of fibrinolysis. TVX/LPS coexposure caused a significant increase in sinusoidal fibrin deposition in the liver at 4.5 h, which was significantly reduced by etanercept treatment (Fig. 5C).

### Table 1

<table>
<thead>
<tr>
<th>Mouse Strain</th>
<th>Necrosis Score</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>4.3</td>
<td>1.7–4.7</td>
<td></td>
</tr>
<tr>
<td>p55+/−</td>
<td>0.5*</td>
<td>0.3–1.1</td>
<td></td>
</tr>
<tr>
<td>p75+/−</td>
<td>0.4*</td>
<td>0.0–1.0</td>
<td></td>
</tr>
</tbody>
</table>

*Significantly different from wild-type group.
TVX and TNFα Coexposure Causes Hepatotoxicity.

TVX/LPS-induced liver injury is dependent on TNFα (Shaw et al., 2007), but to determine whether TNFα alone could interact with TVX, mice were treated with TVX and recombinant murine TNFα as described under Materials and Methods. They were killed 15 h after TNFα treatment, the time of maximal plasma ALT activity in TVX/LPS-treated mice. TVX or TNFα treatment alone did not cause an increase in plasma ALT activity (Fig. 6). However, TVX/TNFα coexposure increased plasma ALT activity. Histopathological evaluation of liver sections corroborated the lack of injury from TVX or TNFα alone (Fig. 7). In contrast, TVX/TNFα coexposure caused hepatocellular necrotic and apoptotic lesions primarily in centrilobular and midzonal regions of liver lobules, and these lesions extended to periportal regions in some severely affected mice.

Discussion

Previously, we reported that a nontoxic dose of TVX interacts with a nontoxic dose of LPS to cause TNFα-dependent liver injury in mice (Shaw et al., 2007). The critical role of TNFα in TVX/LPS-induced liver injury was based upon TNFα neutralization; however, the role of each TNF receptor was not studied. Activation of the p55 receptor results in two main signals: NF-κB activation and activation of caspases leading to apoptosis (Varghese et al., 2001). Inasmuch as ligand binding of the p55 receptor can result in NF-κB activation and cell death, it is not surprising that the p55 receptor is critical to several models of liver injury (Küsters et al., 1997; Peschon et al., 1998; Hayder et al., 1999; Schumann et al., 2000). Indeed, p55−/− mice were completely protected from TVX/LPS-induced liver injury and had significantly reduced hepatocellular injury compared with p55+/+ mice.

Why p55−/− mice are completely protected from TVX/LPS-induced hepatotoxicity is unclear. It is possible that p55−/− mice have reduced liver injury because of decreased plasma TNFα concentrations since TNFα induction by LPS was found to be attenuated in p55−/− mice (Peschon et al., 1998). However, p55 was not involved in the induction of TNFα by galactosamine/LPS coexposure (Nowak et al., 2000).

The function of the p75 receptor is less understood compared with the p55 receptor. Similar to p55, activation of the p75 receptor causes NF-κB activation, but it does not result in caspase activation (Dopp et al., 2002). The critical role of the p75 receptor in hepatotoxicity is unclear: it is not involved in some models of liver injury that are dependent on TNFα (Peschon et al., 1998; Nowak et al., 2000) but is involved in others (Küsters et al., 1997; Hayder et al., 1999; Schumann et al., 2000). Indeed, p75−/− mice were completely protected from TVX/LPS-induced liver injury and had significantly reduced hepatocellular injury compared with p55−/− mice.
cellular necrosis, which is unseen when either receptor is absent. In addition, the p75 receptor is involved in the LPS-induced production of TNFα (Peschon et al., 1998). It is possible that the complete protection in p75−/− mice resulted from a combination of these mechanisms, including a reduction in LPS-induced TNFα production. TNFα was involved in the TVX/LPS-mediated increases in
plasma concentrations of several inflammatory cytokines: IFN-γ, IL-6, MCP-1, VEGF, MIP-2, KC, and MIP-1α. IL-1β concentrations were unchanged by etanercept treatment at 4.5 h; however, IL-1β peaks 2 h after LPS administration, and we are unable to rule out the possibility that etanercept reduced it at an earlier time (Givalois et al., 1994). The attenuation of IL-6 and MIP-2 after TNFα neutralization was also seen in another model of drug/LPS coexposure-induced hepatotoxicity (Tukov et al., 2007). The reduction of such a large number of cytokines might be because of a decrease in TNFα-driven NF-κB activation mediated through p55 and p75 receptor activation (Dopp et al., 2002).

Several of the cytokines that required TNFα for their release have chemotactic properties. Therefore, we measured PMN accumulation in livers of these mice. The hepatic accumulation of PMNs induced by TVX/LPS was not decreased by TNFα inhibition. Thus, it is likely that the TVX/LPS-induced hepatic PMN accumulation is mediated by selectins and other adhesion molecules as seen in endotoxemia or by TNFα-independent sinusoidal contraction (Kamochi et al., 2004). It is possible that TNFα is not involved in PMN accumulation but is needed for PMN activation since TNFα can promote neutrophil activation in vitro (Dri et al., 1999). If TNFα enhances PMN activation and degranulation, it might explain the slight increase in hepatic PMN accumulation in TVX/LPS/etanercept-treated mice because when TNFα is present, the accumulated PMNs might be activated, degranulated, and undergo clearance from the tissue.

In addition to being critical to TVX/LPS up-regulation of cytokines, it is possible that TNFα is involved in the progression of liver injury by enhancing hemostasis. TVX/LPS coexposure caused fibrin deposition in liver sinusoids, and treatment with the anticoagulant heparin significantly reduced TVX/LPS-induced liver injury (Fullerton et al., 2008). TNFα has the potential to interact with the hemostatic system in several ways. It can induce tissue factor, which activates the coagulation system, but it also increases PAI-1 expression, which could depress fibrinolysis (Takeshita et al., 2006; Tukov et al., 2007). Indeed, TVX/LPS-induced increases in active PAI-1 and hepatic fibrin deposition were TNFα-dependent, whereas coagulation system activation showed a trend but was not significantly reduced after TNFα inhibition. The results suggest that if tissue factor induction occurs during TVX/LPS coexposure, it is TNFα-independent, but that a slight reduction in coagulation system activation by etanercept along with a more pronounced reduction in active PAI-1 was able to prevent hepatic fibrin deposition.

From the cytokine studies, TNFα appears to be a proximal mediator in a cascade of inflammatory events synergistically induced by TVX/LPS coexposure. These include the release of cytokines and production of PAI-1 and hepatic fibrin deposition. Several of these factors are known to be involved in TVX/LPS-induced liver injury; however, how they interplay with one another in the pathogenesis is currently being investigated.

Based on the importance of TNFα in TVX/LPS-induced liver injury, we examined whether TVX can interact with a dose of TNFα to induce similar hepatocellular damage. Indeed, TVX treatment before a nonhepatotoxic dose of recombinant murine TNFα resulted in significant liver injury. Other studies have shown that TNFα by itself does not cause liver injury in mice but can when administered with galactosamine or a DNA synthesis inhibitor (Schwabe and Brenner, 2006; Shen and Pervaiz, 2006). It is unclear from these results whether TVX sensitized mice to TNFα-induced liver injury or vice versa. Topoisomerase inhibitors render hepatocytes sensitive to cell death induced by TNFα (Hentze et al., 2004). In accordance, it is possible that TVX renders hepatocytes sensitive to cell death induced by TNFα by affecting eukaryotic topoisomerases and inhibiting protein synthesis. Consistent with this hypothesis, the hepatocellular lesions in TVX/TNFα-treated mice appear similar to those seen after galactosamine/TNFα coexposure, suggesting commonalities in mechanisms (Gezginci and Bolkent, 2007). Recently, CYP2E1 induction by pyrazole was shown to sensitize mice to TNFα-induced liver injury (Wu and Cederbaum, 2008). It is unlikely that TVX/TNFα-induced liver injury is related to an effect on CYP2E1 activity by TVX because TVX treatment alone did not have any effect on CYP2E1 expression (Shaw et al., 2008). However, to exclude this possibility, CYP2E1 activity would need to be measured after TVX exposure. It is also possible that TVX treatment reduced TNFα clearance and that the prolonged presence of TNFα resulted in cell death. This is consistent with the prolonged presence of TNFα in the plasma of TVX/TNFα-treated mice compared with LPS treatment alone (Shaw et al., 2007). TNFα inactivation and clearance are mediated by soluble forms of the two receptors. It is possible that TVX reduces the cleavage or expression of these receptors, in turn reducing TNFα clearance. Further studies are required to understand better the mechanism by which TVX and TNFα interact to cause hepatocellular damage.

In summary, TVX/LPS-induced liver injury depended on the presence of both TNF receptors, p55 and p75. The p75 receptor may play an even more important role than the p55 receptor in the progression of TVX/LPS-induced hepatotoxicity. At the onset of liver injury, the TVX/LPS coexposure-related increase in several cytokines, active PAI-1, and hepatic fibrin was TNFα-dependent. However, despite the observation that the induction of chemokines was TNFα-dependent, hepatic PMN accumulation was independent of TNFα. The critical role of TNFα in TVX/LPS-induced liver injury is not yet understood.
injury was likely through up-regulation of cytokines and activation of the hemostatic system. The observation that the liver injury could be reproduced by substituting TNFαs administration for LPS supports the critical importance of this cytokine in the pathogenesis.

References

Address correspondence to: Dr. Robert Roth, 221 Food Safety Building, Michigan State University, East Lansing, MI 48824. E-mail: rothr@msu.edu